Our Story
We are a late-stage biopharmaceutical company dedicated to developing transformative therapies for rare diseases with serious unmet needs. The patient is at the core of every decision we make—from how we develop medicines, to the team we build that brings them to fruition—and we are resolved in our commitment to make a difference.
Hypoglycemia as a result of hyperinsulinism can strike in many forms. From infants with inherited disease to adults battling late-stage cancer, we are driven to empower individuals to restore balance within their lives, and we will continue to work with our partners around the world to fight hyperinsulinism in all its forms.
Disease Focus: Hyperinsulinism
Congenital hyperinsulinism (HI) is a rare genetic disease that presents very early in life and is characterized by excess and erratic insulin secretion that can cause infants, children, and adults to become dangerously hypoglycemic and starve their bodies of glucose.
Tumor hyperinsulinism (HI) may be caused by two distinct types of tumors: islet cell tumors (ICTs) and non-islet cell tumors (NICTs), both of which lead to hypoglycemia due to excessive activation of the insulin receptor.
Now enrolling
Phase III sunRIZE Trial in the study of congenital hyperinsulinism
